Key facts
- Alloy (Pharmaceuticals)’s last known valuation is $160.0M.
- It has raised $18.3M; the latest was Later Stage VC ($15.8M) in Nov 2024.
- Notable investors include Matter (Consulting Services (B2B)), Kinled Holding, Amboy Street Ventures, Seven Hound Ventures, Emmeline Ventures — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Alloy (Pharmaceuticals)
- ·The full record, as it builds
Funding rounds
No funding rounds for Alloy (Pharmaceuticals) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Alloy (Pharmaceuticals)
Developer of women's health care products intended to promote wellness and manage menopause effectively. The company's products include a line of natural items created for conditions like menopause, osteoporosis, and weight gain, enabling women to live a healthy and long life.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2019
- Employees
- 45
- Website
- myalloy.com/
- Ownership
- Privately Held (backing)
Alloy (Pharmaceuticals) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Alloy (Pharmaceuticals) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Alloy (Pharmaceuticals) in its N-PORT filings yet. We sweep new filings monthly.